SPRUCE BIOSCIENCES, INC.SPRBEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Spruce Biosciences, Inc. is a late-stage biopharmaceutical firm focused on developing targeted therapies for rare endocrine and metabolic disorders with high unmet medical need. Its core pipeline includes candidates for congenital adrenal hyperplasia and Cushing’s syndrome, serving patients across North America, Europe and other developed markets.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| HealthCap VIII, L.P. | 8.90% | 3.7M | — | 2024-03-07 |
| Bradley L. Radoff | 6.90% | 2.8M | — | 2024-03-28 |
| Rock Springs Capital Management LP | 6.41% | 2.6M | — | 2024-02-14 |
| Armistice Capital, LLC | 4.99% | 2.2M | ▼ -0.49pp | 2024-11-14 |
| Dr. Kush Parmar | 4.10% | 1.8M | — | 2024-11-14 |
| NO. | 4.00% | 1.6M | — | 2023-05-30 |
| Aisling Capital V, LP | 3.00% | 1.2M | — | 2024-02-06 |
| The Radoff Family Foundation | 1.00% | 175.0K | — | 2024-11-12 |
| Citadel Advisors LLC | 0.20% | 40.7M | — | 2024-02-14 |
| NOS. OF ABOVE PERSONS | 0.00% | 41.3M | ▼ -3.67pp | 2024-10-23 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.